India, June 2 -- Shares of Lyra Therapeutics, Inc. (LYRA) soared 480% on Monday morning after the clinical-stage biotechnology company announced positive results from the phase 3 trial of LYR-210, which achieving statistically significant results for primary and key secondary endpoints in the treatment of chronic rhinosinusitis.
LYRA is currently trading at $28.63, down $23.70 or 480.73%, on a volume of 16.7 million shares, above average volume of 69 thousand, on the Nasdaq. The stock opened at $28.99 after closing Friday at $4.93. The stock has traded between $3.81 and $37.50 in the past 52-week period.
The trial met its primary endpoint, with LYR-210 demonstrating statistically significant improvement compared to sham control in a compo...